Journals / Türk Kardiyoloji Derneği Arşivi / 2011 / Cilt: 39 - Sayı: 5

Metabolik sendromlu olgularda koroner arter hastalığının paraoksonaz-1 aktivitesi ile ilişkisi

The relationship between paraoxonase-1 activity and coronary artery disease in patients with metabolic syndrome

Pages
371–377
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall PON-1 activity of all the subjects showed no correlation with the parameters examined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We investigated the correlation of serum paraoxonase-1 (PON-1) activity with coronary artery disease (CAD) in patients with metabolic syndrome (MetS).
📊
Key Findings & Data:Study design: The study included 21 patients (mean age 55±9 years) with MetS, stable angina pectoris, and angiographically shown CAD, 24 patients (mean age 51±10 years) with MetS and angiographically normal coroner arteries, and 28 healthy controls (mean age 49±12 years).
💡
Conclusion & Impact:The overall PON-1 activity of all the subjects showed no correlation with the parameters examined.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: We investigated the correlation of serum paraoxonase-1 (PON-1) activity with coronary artery disease (CAD) in patients with metabolic syndrome (MetS). Study design: The study included 21 patients (mean age 55±9 years) with MetS, stable angina pectoris, and angiographically shown CAD, 24 patients (mean age 51±10 years) with MetS and angiographically normal coroner arteries, and 28 healthy controls (mean age 49±12 years). Demographic and clinical characteristics, insulin levels, homeostasis model assessment of insulin resistance index, and PON-1 activity were assessed in all the groups. Severity of CAD was assessed using the Gensini score. Results: Paraoxonase-1 activity was significantly lower in patients with MetS compared to the control group (p=0.02). The two MetS groups with and without CAD exhibited similar characteristics in all the parameters including PON-1 activity (p>0.05). Univariate correlation analysis performed in MetS-CAD patients showed a significant negative correlation between the Gensini score and PON-1 activity (r=-0.48, p=0.02). The overall PON-1 activity of all the subjects showed no correlation with the parameters examined. Conclusion: Decreased PON-1 activity in patients with MetS compared to the control group suggests increased oxidative stress in MetS. Detection of similar PON-1 activity levels in MetS groups with and without CAD suggests that disturbance of oxidative-antioxidative balance occurs before the development of CAD. The negative correlation between the Gensini score and PON-1 activity implies that decreased PON-1 activity may be one of the etiologic causes of atherosclerotic progress in MetS.

Özet

Amaç: Bu çalışmada, metabolik sendrom (MetS) olan hastalarda serum paraoksonaz-1 (PON-1) aktivitesinin koroner arter hastalığı (KAH) ile ilişkisi araştırıldı.Çalışma planı: Ç alışmaya, M etS, k ararlı a ngina p ektoris ve anjiyografik olarak KAH bulunan 21 hasta (ort. yaş 55±9), anjiyografide koroner arterleri normal bulunan MetS’li 24 hasta (ort. yaş 51±10) ve 28 sağlıklı birey (ort. yaş 49±12) alındı. Hasta ve kontrol gruplarında demografik ve klinik özellikler, insülin düzeyi, homeostaz modeliyle değerlendirilen insülin direnci indeksi ve PON-1 aktivitesi değerlendirildi. Koroner arter hastalığının ciddiyeti Gensini skoruyla değerlendirildi.Bulgular: Kontrol grubuyla karşılaştırıldığında, MetS’li hastalarda PON-1 aktivitesi anlamlı derecede daha düşük bulundu (p=0.02). Buna karşın, KAH’li ve KAH’siz MetS gruplarında PON-1 aktivitesi de dahil, incelenen hiçbir parametrede anlamlı fark saptanmadı (p>0.05). Koroner arter hastalığı olan grupta yapılan tekdeğişkenli korelasyon analizinde, Gensini skoru ile PON-1 aktivite düzeyi arasında anlamlı negatif ilişki gözlendi (r=-0.48, p=0.02). Tüm olguların alındığı analizde ise, PON-1 aktivitesi incelenen hiçbir parametre ile anlamlı ilişki göstermedi.Sonuç: Kontrol grubuyla karşılaştırıldığında, MetS’li hastalarda PON-1 aktivitesindeki azalma oksidatif stres artışını düşündürmektedir. İki MetS grubunda (KAH’li ve KAH’siz) PON-1 aktivitesinin benzer bulunması, oksidatif-antioksidatif dengenin KAH oluşumu öncesinde bozulduğunu düşündürmektedir. Gensini skoru ile PON-1 aktivitesi arasındaki negatif ilişki ise, düşük PON-1 aktivitesinin MetS’li hastalarda ateroskleroz gelişmesinden sorumlu olan nedenlerden biri olduğunu akla getirmektedir.

🔖

Cite This Article

AKKUŞ, N., ÇİMEN, B., SEYİS, S., ÖZCAN, T., ÇİÇEK, D., ÇELEBİ, B., DÖVEN, O., ÇAMSARI, A., CİN, G., AKÇAY, A. B. (2022). Metabolik sendromlu olgularda koroner arter hastalığının paraoksonaz-1 aktivitesi ile ilişkisi. Türk Kardiyoloji Derneği Arşivi, Cilt: 39 - Sayı: 5, 371–377. https://ajindex.com/articles/633099

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113-9
  2. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507
  3. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-83
  4. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7:69-76
  5. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-5
  6. Kabaroğlu C, Mutaf İ, Boydak B, Özmen D, Habif S, Erdener D, et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol 2004;59:606-11
  7. Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas MI, Sala J, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003;88:5422-6
  8. Peppes V, Rammos G, Manios E, Koroboki E, Rokas S, Zakopoulos N. Correlation between myocardial enzyme serum levels and markers of inflammation with severity of coronary artery disease and Gensini score: a hospitalbased, prospective study in Greek patients. Clin Interv Aging 2008;3:699-710
  9. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295-300
  10. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001;131:2082-9. 11. van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a dietcontrolled, randomised intervention study in middle-aged men. Atherosclerosis 1999;147:405-10
  11. Chandra M, Chandra N, Agrawal R, Kumar A, Ghatak A, Pandey VC. The free radical system in ischemic heart disease. Int J Cardiol 1994;43:121-5
  12. Taşkıran P, Cam SF, Sekuri